From the INVICTUS Trial to Current Considerations: It’s Not Time to Retire Vitamin K Inhibitors Yet!
Atrial fibrillation (AF) is a common arrhythmia in clinical practice, and oral anticoagulation is the cornerstone of stroke prevention in AF. Direct oral anticoagulants (DOAC) significantly reduce the incidence of intracerebral hemorrhage with preserved efficacy for preventing stroke compared to vit...
Saved in:
| Main Authors: | Akshyaya Pradhan, Somya Mahalawat, Marco Alfonso Perrone |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/11/1459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of patients with acquired valvular heart disease in noncardiac surgery
by: O. B. Irtyuga, et al.
Published: (2021-09-01) -
Optimal anticoagulation strategy for atrial fibrillation ablation: are all direct oral anticoagulants and vitamin K antagonists the same? - a meta-analysis of embolic and bleeding complications in more than 31,500 patients
by: Musat Dan L, et al.
Published: (2025-06-01) -
Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series
by: Ping Jin, et al.
Published: (2024-12-01) -
ANTITHROMBOTIC THERAPY IN PATIENTS WITH VALVULAR HEART DISEASE: WHAT'S NEW?
by: N. A. Shostak, et al.
Published: (2017-12-01) -
Direct oral anticoagulants (DOACs): From the laboratory point of view
by: Margetić Sandra, et al.
Published: (2022-12-01)